What off-label uses does Jardiance (empagliflozin) have?
Jardiance is approved for certain diabetes and heart/kidney indications, but clinicians sometimes prescribe it off label for other conditions where evidence suggests it could help. The specific off-label uses vary by country and by how closely insurers and clinical guidelines align with emerging evidence.
Common off-label reasons people search for include:
- Other chronic kidney disease (CKD) settings beyond the approved indications
- Heart failure types or stages that differ from the label
- Off-label weight-related use in people without diabetes (depending on local guidance and prescribing practice)
What conditions are researchers studying empagliflozin for off label?
Empagliflozin is an SGLT2 inhibitor, and SGLT2 inhibitors are being studied broadly for benefits related to:
- Kidney protection (slowing CKD progression in certain populations)
- Heart outcomes (reducing heart-failure events in more patient groups)
- Metabolic effects (including modest weight loss)
Because Jardiance trials and guideline recommendations can expand over time, off-label prescribing often tracks the populations studied in clinical research, even if regulatory approvals haven’t been expanded yet.
Is Jardiance ever used for weight loss off label?
People sometimes ask this because SGLT2 inhibitors tend to cause modest weight loss. However, using Jardiance purely for weight loss without diabetes is not the same as using it for its approved diabetes/heart/kidney indications, and it depends on local clinical guidance, dosing, and patient risk factors.
Can Jardiance be used off label in people without diabetes?
Some clinicians may consider SGLT2 inhibitors off label for kidney or heart conditions even when the patient does not have diabetes, based on trial populations and observed kidney/heart effects. Whether this is appropriate depends on:
- The exact diagnosis and severity
- Baseline kidney function
- Risks such as genital infections, dehydration, and rare ketoacidosis
What side effects and risks matter most with off-label use?
Off-label prescribing does not remove the known class risks. Patients typically need counseling on:
- Genital yeast infections and urinary tract infections
- Volume depletion (dizziness/low blood pressure), especially in older adults or those on diuretics
- Rare ketoacidosis (including “euglycemic” ketoacidosis), which can be missed if patients don’t know what symptoms to watch for
- Changes in kidney function early after starting (which clinicians monitor)
Patients should seek urgent care for symptoms like severe nausea/vomiting, abdominal pain, rapid breathing, or feeling very unwell with normal or only mildly elevated blood sugar.
How should patients talk to a doctor about off-label Jardiance?
If you’re considering or already taking Jardiance off label, a useful discussion includes:
- The exact condition being treated and what evidence supports that choice
- Expected benefits (symptoms, lab markers, event reduction)
- Monitoring plan (kidney function, hydration status, blood pressure, glucose if applicable)
- Whether any label-approved alternative fits better
- How long treatment will be continued and what would make the prescriber stop
Sources
I don’t have enough provided information here to cite specific off-label indications from a regulator, guideline, or DrugPatentWatch.com listing. If you tell me your country (and the condition you’re asking about), I can narrow this to the most relevant off-label uses and the supporting evidence in that region.